Table 2 Baseline characteristics between the nintedanib group and no antifibrotic therapy group in historical control study
IPF patients with LTOT (n = 19) | P value | IPF patients without LTOT (n = 12) | P value | |||
|---|---|---|---|---|---|---|
Nintedanib | No antifibrotic therapy | Nintedanb | No antifibrotic therapy | |||
(n = 9) | (n = 10) | (n = 7) | (n = 5) | |||
Age (years) | 69 [57–77] | 72 [60–83] | 0.315 | 73 [64–80] | 70 [48–76] | 0.639 |
Male | 8 (88%) | 6 (60%) | 0.153 | 6 (86%) | 4 (80%) | 0.793 |
Weight (kg) | 68.7 [43.3–73.9] | 54.7 [26.0–72.0] | 0.065 | 59.6 [44.3–61.5] | 52.9 [46.9–63.0] | 0.876 |
Body mass index | 25.1 [15.1–26.9] | 20.2 [13.7–28.8] | 0.661 | 22.0 [19.0–26.7] | 20.7 [18.6–26.7] | 0.876 |
Smoking status | ||||||
Never / Former / Current smoker | 0 / 9 / 0 | 3 / 7 / 0 | – | 0 / 7 / 0 | 1 / 4 / 0 | – |
Time since the diagnosis of IPF (years) | 2 [0–9] | 1 [0–3] | 0.400 | 4 [1–8] | 3 [0–4] | 0.202 |
mMRC dyspnea scale | 3 [0–3] | 2 [1–3] | 0.842 | 1 [0–2] | 2 [0–3] | 0.343 |
GAP score | 5 [2–8] | 5 [1–7] | 0.796 | 4 [3–5] | 5 [2–5] | 0.648 |
SpO2 on room air at rest (%) | 95 [94–97] | 95 [89–98] | 0.573 | 97 [94–99] | 96 [95–98] | 0.648 |
PaO2 on room air at rest (mmHg) | 75 [59–94] | 70 [47–89] | 0.277 | 88 [81–122] | 91 [75–103] | 0.927 |
PASP measured by TTE at baseline (mmHg) | 33.0 [21.0–59.0] | 41.4 [31–56.2] | 0.278 | 35.0 [27.6–55.3] | 37.0 [27.9–56.2] | 0.775 |
Pulmonary function tests | ||||||
FVC (mL) | 2.140 [1.060–3.030] | 1.735 [1.170–2.480] | 0.278 | 1.840 [1.540–2.690] | 2.020 [1.060–2.370] | 0.953 |
FVC (% predicted) | 66 [28–88] | 61 [46–74] | 0.720 | 57 [51–79] | 64 [35–73] | 0.530 |
FEV1 (mL) | 1.990 [1.030–2.407] | 1.560 [1.010–2.280] | 0.356 | 1.560 [1.330–2.270] | 1.930 [1.050–2.100] | 1.000 |
FEV1 (% predicted) | 67 [34–91] | 72 [56–83] | 0.549 | 76 [50–81] | 73 [40–85] | 0.876 |
DLCO (mL/min/mmHg) | 8.3 [5.1–13.6] | 6.6 [4.3–11.7] | 0.091 | 10.7 [8.1–18.6] | 10.0 [7.3–16.3] | 0.788 |
DLCO (% predicted) | 49 [30–76] | 40 [29–73] | 0.299 | 70 [48–91] | 74 [38–129] | 1.000 |
Radiographic findings | ||||||
Pulmonary emphysema | 5 (56%) | 3 (30%) | 0.414 | 1 (14%) | 1 (20%) | 0.682 |
Comorbidity | ||||||
Hypertension | 3 (33%) | 4 (40%) | 0.764 | 3 (43%) | 1 (20%) | 0.408 |
Chronic heart failure | 0 (0%) | 0 (0%) | – | 0 (0%) | 0 (0%) | – |
No antifibrotic agent | ||||||
No treatment | – | 3 (30%) | – | – | 1 (20%) | – |
Corticosteroid monotherapy | – | 1 (10%) | – | – | 2 (40%) | – |
Combined corticosteroid and immunomodulator therapy | – | 5 (50%) | – | – | 2 (40%) | – |
Inhalation of N-acetyl-cysteine | – | 1 (10%) | – | – | 0 (0%) | – |